These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 30175979)

  • 1. Metabolomics Analyses of Saliva Detect Novel Biomarkers of Alzheimer's Disease.
    Huan T; Tran T; Zheng J; Sapkota S; MacDonald SW; Camicioli R; Dixon RA; Li L
    J Alzheimers Dis; 2018; 65(4):1401-1416. PubMed ID: 30175979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic Biomarkers of Alzheimer's Disease as Identified in Saliva using 1H NMR-Based Metabolomics.
    Yilmaz A; Geddes T; Han B; Bahado-Singh RO; Wilson GD; Imam K; Maddens M; Graham SF
    J Alzheimers Dis; 2017; 58(2):355-359. PubMed ID: 28453477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma metabolic profiling of mild cognitive impairment and Alzheimer's disease using liquid chromatography/mass spectrometry.
    Liu Y; Li N; Zhou L; Li Q; Li W
    Cent Nerv Syst Agents Med Chem; 2014; 14(2):113-20. PubMed ID: 25515716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Community-Based Study Identifying Metabolic Biomarkers of Mild Cognitive Impairment and Alzheimer's Disease Using Artificial Intelligence and Machine Learning.
    Yilmaz A; Ustun I; Ugur Z; Akyol S; Hu WT; Fiandaca MS; Mapstone M; Federoff H; Maddens M; Graham SF
    J Alzheimers Dis; 2020; 78(4):1381-1392. PubMed ID: 33164929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer's Biomarkers From Multiple Modalities Selectively Discriminate Clinical Status: Relative Importance of Salivary Metabolomics Panels, Genetic, Lifestyle, Cognitive, Functional Health and Demographic Risk Markers.
    Sapkota S; Huan T; Tran T; Zheng J; Camicioli R; Li L; Dixon RA
    Front Aging Neurosci; 2018; 10():296. PubMed ID: 30333744
    [No Abstract]   [Full Text] [Related]  

  • 6. Plasma metabolite profiles of Alzheimer's disease and mild cognitive impairment.
    Wang G; Zhou Y; Huang FJ; Tang HD; Xu XH; Liu JJ; Wang Y; Deng YL; Ren RJ; Xu W; Ma JF; Zhang YN; Zhao AH; Chen SD; Jia W
    J Proteome Res; 2014 May; 13(5):2649-58. PubMed ID: 24694177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of isotope labeling LC-MS for human salivary metabolomics and application to profiling metabolome changes associated with mild cognitive impairment.
    Zheng J; Dixon RA; Li L
    Anal Chem; 2012 Dec; 84(24):10802-11. PubMed ID: 23150892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salivaomics as a Potential Tool for Predicting Alzheimer's Disease During the Early Stages of Neurodegeneration.
    François M; Karpe A; Liu JW; Beale D; Hor M; Hecker J; Faunt J; Maddison J; Johns S; Doecke J; Rose S; Leifert WR
    J Alzheimers Dis; 2021; 82(3):1301-1313. PubMed ID: 34151801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acyl-Alkyl-Phosphatidlycholines are Decreased in Saliva of Patients with Alzheimer's Disease as Identified by Targeted Metabolomics.
    Marksteiner J; Oberacher H; Humpel C
    J Alzheimers Dis; 2019; 68(2):583-589. PubMed ID: 30814361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of chemical isotope labeling LC-MS for tissue metabolomics and its application for brain and liver metabolome profiling in Alzheimer's disease mouse model.
    Wang X; Han W; Yang J; Westaway D; Li L
    Anal Chim Acta; 2019 Mar; 1050():95-104. PubMed ID: 30661596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics.
    Trushina E; Dutta T; Persson XM; Mielke MM; Petersen RC
    PLoS One; 2013; 8(5):e63644. PubMed ID: 23700429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study.
    Varma VR; Oommen AM; Varma S; Casanova R; An Y; Andrews RM; O'Brien R; Pletnikova O; Troncoso JC; Toledo J; Baillie R; Arnold M; Kastenmueller G; Nho K; Doraiswamy PM; Saykin AJ; Kaddurah-Daouk R; Legido-Quigley C; Thambisetty M
    PLoS Med; 2018 Jan; 15(1):e1002482. PubMed ID: 29370177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of novel diagnostic panel for mild cognitive impairment and Alzheimer's disease: findings based on urine proteomics and machine learning.
    Wang Y; Sun Y; Wang Y; Jia S; Qiao Y; Zhou Z; Shao W; Zhang X; Guo J; Zhang B; Niu X; Wang Y; Peng D
    Alzheimers Res Ther; 2023 Nov; 15(1):191. PubMed ID: 37925455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a Metabolic Signature Predisposing High Risk Patients with Mild Cognitive Impairment to Converting to Alzheimer's Disease.
    Huang YL; Lin CH; Tsai TH; Huang CH; Li JL; Chen LK; Li CH; Tsai TF; Wang PN
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Widely targeted metabolomics of Alzheimer's disease postmortem cerebrospinal fluid based on 9-fluorenylmethyl chloroformate derivatized ultra-high performance liquid chromatography tandem mass spectrometry.
    Muguruma Y; Tsutsui H; Noda T; Akatsu H; Inoue K
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Aug; 1091():53-66. PubMed ID: 29852382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urine metabolomics phenotyping and urinary biomarker exploratory in mild cognitive impairment and Alzheimer's disease.
    Wang Y; Sun Y; Wang Y; Jia S; Qiao Y; Zhou Z; Shao W; Zhang X; Guo J; Song X; Niu X; Peng D
    Front Aging Neurosci; 2023; 15():1273807. PubMed ID: 38187356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of isotope labeling liquid chromatography mass spectrometry for mouse urine metabolomics: quantitative metabolomic study of transgenic mice related to Alzheimer's disease.
    Peng J; Guo K; Xia J; Zhou J; Yang J; Westaway D; Wishart DS; Li L
    J Proteome Res; 2014 Oct; 13(10):4457-69. PubMed ID: 25164377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
    Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
    Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paired plasma lipidomics and proteomics analysis in the conversion from mild cognitive impairment to Alzheimer's disease.
    Gómez-Pascual A; Naccache T; Xu J; Hooshmand K; Wretlind A; Gabrielli M; Lombardo MT; Shi L; Buckley NJ; Tijms BM; Vos SJB; Ten Kate M; Engelborghs S; Sleegers K; Frisoni GB; Wallin A; Lleó A; Popp J; Martinez-Lage P; Streffer J; Barkhof F; Zetterberg H; Visser PJ; Lovestone S; Bertram L; Nevado-Holgado AJ; Gualerzi A; Picciolini S; Proitsi P; Verderio C; Botía JA; Legido-Quigley C
    Comput Biol Med; 2024 Jun; 176():108588. PubMed ID: 38761503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in metabolic pathways and networks in Alzheimer's disease.
    Kaddurah-Daouk R; Zhu H; Sharma S; Bogdanov M; Rozen SG; Matson W; Oki NO; Motsinger-Reif AA; Churchill E; Lei Z; Appleby D; Kling MA; Trojanowski JQ; Doraiswamy PM; Arnold SE;
    Transl Psychiatry; 2013 Apr; 3(4):e244. PubMed ID: 23571809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.